Novavax completes enrolling 30,000 people in U.S. trial of COVID-19 vaccine

Go back to Novavax completes enrolling 30,000 people in U.S. trial of COVID-19 vaccine
Novavax, Inc. (NASDAQ: NVAX) Delayed: 127.82 -10.36 (7.5%)
Previous Close $138.18    52 Week High $9.23 
Open $132.50    52 Week Low $1.16 
Day High $139.86    P/E N/A 
Day Low $125.46    EPS $-0.30 
Volume 4,738,402